Find information on thousands of medical conditions and prescription drugs.

Velcade

Bortezomib (marketed as Velcade™ by Millenium Pharmaceuticals) is a "first-in-class" proteasome inhibitor. It is the best studied of a next generation of anti-myeloma drugs, and is also a potential treatment for plasma cell leukemia. more...

Home

Vagifem

Valcyte

Valine

Valium

Valstar

Valtrex

Vaniqa

Velcade

Velivet

Venlafaxine

Ventolin

Vepesid

Verapamil

Verelan

Vermox

Versed

Vfend

Viadur

Viagra

Vicoprofen

Vidarabine

Vidaza

Videx

Vioxx

Viread

Visine

Vistide

Visudyne

Vitaped

Vitrase

Vivelle

Volmax

Voltaren

Voriconazole

Vosol

Bortezomib works by blocking the action of 26S proteasome, which is a multicatalytic enzyme whose function is to degrade abnormal or misfolded proteins targeted for destruction. There is emerging evidence that 26S proteasome plays a role in myeloma and lymphoma.

The Multiple Myeloma Research Foundation was responsible for a substantial amount of the funding for the development and testing of this drug.

Side effects

Bortezomib is associated with peripheral neuropathy in 30% of patients; occasionally, it can be painful. This can be worse in patients with pre-existing neuropathy. In addition, myelosuppression as neutropenia and thrombocytopenia can also occur and be dose limiting.

Links

Millenium Pharmaceuticals website on Velcade™
International Myeloma Foundation article on Velcade™
US Food and Drugs Administration on Velcade™
Dedicated website for European audience

Read more at Wikipedia.org

• [List your site here Free!]



	VELCADE® for Injection Continues to Show Impressive Results in a Variety of Lymphomas -- High single-agent and combination therapy response rates reported -- ATLANTA, Dec. 12 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. From PR Newswire, 12/12/05

	VELCADE® for Injection Single-Agent and Combination Studies Show Positive Outcomes in a Broad Range of Multiple Myeloma Patients - High response rates also seen in patients with renal impairment or chromosome 13 deletions - ATLANTA, Dec. 12 /PRNewswire-FirstCall/ -- Millennium ... From PR Newswire, 12/12/05

	Consistently High Complete and Overall Response Rates in Newly-Diagnosed Multiple Myeloma Patients Shown With Velcade® for Injection Based Therapies ATLANTA, Dec. 13 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced results from studies exploring VELCADE alone, or in combination ... From PR Newswire, 12/13/05

	New Data Show Median 30-Month Survival With VELCADE® for Injection in Relapsed Multiple Myeloma - Single-agent data demonstrate six-month survival advantage over dexamethasone - ATLANTA, Dec. 11 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, ... From PR Newswire, 12/11/05

	New Data on VELCADE® for Injection to Be Presented at Upcoming American Society of Hematology Meeting -- Featured in 117 abstracts including 14 oral presentations and 72 posters -- CAMBRIDGE, Mass., Dec. 6 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, ... From PR Newswire, 12/6/05

	Millennium Announces Webcast of Data on VELCADE® for Injection From the 47th Annual Meeting of the American Society of Hematology CAMBRIDGE, Mass., Dec. 8 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. will hold a live webcast of its conference call at 8:00 a.m. EST ... From PR Newswire, 12/8/05

	Taking on a lethal blood cancer Non-Hodgkin's lymphoma is mainly a malignancy of antibody-making immune cells called B lymphocytes. While drugs have helped many patients fend off some ... From Science News, 1/1/05 by Nathan Seppa

	Breakdown: how three chemists took the prize: Nobel laureates discovered how cells label proteins for destruction This years Nobel Prize in Chemistry has gone to three scientists--two Israeli and one U.S.--for their discovery of the molecular machinery that cells ... From Science News, 10/16/04 by A. Goho

Home

Contact

Resources

Exchange Links

ebay